Identification of 10 Candidate Biomarkers Distinguishing Tuberculous and Malignant Pleural Fluid by Proteomic Methods
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Pleural effusion, an accumulation of fluid in the pleural space, usually occurs in patients when the rate of fluid formation exceeds the rate of fluid removal. The differential diagnosis of tuberculous pleurisy and malignant pleural effusion is a difficult task in high tuberculous prevalence areas. The aim of the present study was to identify novel biomarkers for the diagnosis of pleural fluid using proteomics technology. Materials and Methods: We used samples from five patients with transudative pleural effusions for internal standard, five patientswith tuberculous pleurisy, and the same numbers of patients having malignant effusions were enrolled in the study. We analyzedthe proteins in pleural fluid from patients using a technique that combined two-dimensional liquid-phase electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Results: We identified a total of 10 proteins with statistical significance. Among 10 proteins, trasthyretin, haptoglobin, metastasis-associated protein 1, t-complex protein 1, and fibroblast growth factor-binding protein 1 were related with malignant pleural effusionsand human ceruloplasmin, lysozyme precursor, gelsolin, clusterin C complement lysis inhibitor, and peroxirexdoxin 3 were expressed several times or more in tuberculous pleural effusions. Conclusion: Highly expressed proteins in malignant pleural effusion were associated with carcinogenesis and cell growth, and proteins associated with tuberculous pleural effusion played a role in the response to inflammation and fibrosis. These findings will aid in the development of novel diagnostic tools for tuberculous pleurisy and malignant pleural effusion of lung cancer.
Abstract
Purpose: Pleural effusion, an accumulation of fluid in the pleural space, usually occurs in patients when the rate of fluid formation exceeds the rate of fluid removal. The differential diagnosis of tuberculous pleurisy and malignant pleural effusion is a difficult task in high tuberculous prevalence areas. The aim of the present study was to identify novel biomarkers for the diagnosis of pleural fluid using proteomics technology. Materials and Methods: We used samples from five patients with transudative pleural effusions for internal standard, five patientswith tuberculous pleurisy, and the same numbers of patients having malignant effusions were enrolled in the study. We analyzedthe proteins in pleural fluid from patients using a technique that combined two-dimensional liquid-phase electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Results: We identified a total of 10 proteins with statistical significance. Among 10 proteins, trasthyretin, haptoglobin, metastasis-associated protein 1, t-complex protein 1, and fibroblast growth factor-binding protein 1 were related with malignant pleural effusionsand human ceruloplasmin, lysozyme precursor, gelsolin, clusterin C complement lysis inhibitor, and peroxirexdoxin 3 were expressed several times or more in tuberculous pleural effusions. Conclusion: Highly expressed proteins in malignant pleural effusion were associated with carcinogenesis and cell growth, and proteins associated with tuberculous pleural effusion played a role in the response to inflammation and fibrosis. These findings will aid in the development of novel diagnostic tools for tuberculous pleurisy and malignant pleural effusion of lung cancer.
참고문헌 (30)
- Egan AM, "Malignant pleural effusion", QJM, 107, pp.179~184 (2014)
- Glaziou P, "Global burden and epidemiology of tuberculosis", Clin Chest Med, 30, pp.621~636 (2009)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- 박지영, "Epidemiology of Lung Cancer in Korea: Recent Trends", Tuberculosis and Respiratory Diseases, 79(2), pp.58~69 (2016), 대한결핵및호흡기학회
- Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)
- O’Farrell PH, "High resolution two-dimensional electrophoresis of proteins", J Biol Chem, 250, pp.4007~4021 (1975)
- Wessel D, "A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids", Anal Biochem, 138, pp.141~143 (1984)
- Tonge R, "Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology", Proteomics, 1, pp.377~396 (2001)
- Lee CL, "Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines", Proteomics, 3, pp.2472~2486 (2003)
- Gharbi S, "Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system", Mol Cell Proteomics, 1, pp.91~98 (2002)
- Alban A, "A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard", Proteomics, 3, pp.36~44 (2003)
- National Lung Screening Trial Research Team, "Reduced lung-cancer mortality with low-dose computed tomographic screening", N Engl J Med, 365, pp.395~409 (2011)
- Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
- Lee CK, "Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis", J Natl Cancer Inst, 105, pp.595~605 (2013)
- Kwak EL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
- Bhatt M, "Pulmonary tuberculosis as differential diagnosis of lung cancer", South Asian J Cancer, 1, pp.36~42 (2012)
- Tyan YC, "Proteomic analysis of human pleural effusion", Proteomics, 5, pp.1062~1074 (2005)
- Maciel CM, "Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients", J Exp Ther Oncol, 5, pp.31~38 (2005)
- Beckman G, "Haptoglobin groups and lung cancer", Hum Hered, 36, pp.258~260 (1986)
- Benkmann HG, "Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients", Hum Hered, 37, pp.290~293 (1987)
- Yee J, "Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection", J Clin Oncol, 27, pp.2787~2792 (2009)
- Ulivi P, "Multiple marker detection in peripheral blood for NSCLC diagnosis", PLoS One, 8, pp.e57401~ (2013)
- Toh Y, "The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications", Clin Exp Metastasis, 26, pp.215~227 (2009)
- Sasaki H, "Expression of the MTA1 mRNA in advanced lung cancer", Lung Cancer, 35, pp.149~154 (2002)
- Yokota S, "Cytosolic chaperonin is upregulated during cell growth. Preferential expression and binding to tubulin at G(1)", S transition through early S phase, 1999, pp.274, 37070~37078
- Yokota S, "Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma", Cell Stress Chaperones, 6, pp.345~350 (2001)
- Sauter ER, "Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental human squamous epithelium", Int J Cancer, 92, pp.374~381 (2001)
- Cernat RI, "Serum trace metal and ceruloplasmin variability in individuals treated for pulmonary tuberculosis", Int J Tuberc Lung Dis, 15, pp.1239~1245 (2011)
- Oikonomou N, "Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis", Thorax, 64, pp.467~475 (2009)
- Rhee SG, "Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling", Free Radic Biol Med, 38, pp.1543~1552 (2005)